TIDMSCLP
RNS Number : 4842O
Scancell Holdings Plc
01 February 2023
1 February 2023
Scancell Holdings Plc
("Scancell" or the "Company")
Directorate Change
Scancell appoints Dr Jean-Michel Cosséry as Non-Executive
Chairman of the Board
Jean-Michel brings 25 years of experience in the international
pharmaceutical and biotech industries
both in an executive and non-executive capacity
Scancell Holdings plc (AIM: SCLP), the developer of novel
immunotherapies for the treatment of cancer and infectious disease,
today announces the appointment of Dr Jean-Michel Cosséry, as
Non-Executive Chairman of the Board of Directors with immediate
effect. As previously announced, Dr John Chiplin who has served as
Chairman since 2016, will step down following Jean-Michel's
appointment . Jean-Michel will seek to drive Scancell's strategy
for clinical progress and commercial development of its novel
immunotherapy vaccine and antibody platforms.
Jean-Michel brings to Scancell over 25 years of experience in
the pharmaceutical and biotechnology industries and a sustained
global track record of success in commercial operations as well as
in capital raising, US and European public offerings, business
development and M&A. Jean-Michel was Vice President for North
America Oncology at Eli Lilly, with responsibility for
commercialisation of the company's oncology portfolio . Preceding
this US-based position, he was Vice President and Managing Director
of the Eli Lilly's European Northern Hub, where he was Chair of the
Eli Lilly UK Board and a member of Lilly European Executive
Committee. Prior to this Jean-Michel served as VP and Chief
Marketing Officer at GE Healthcare's Global Headquarters.
Following his retirement from Eli Lilly in 2018, Jean-Michel has
served on the board of Kymab until their acquisition by Sanofi. He
was also a member of the Immunocore board prior to the company's
Nasdaq listing. Jean-Michel currently serves on the boards of Malin
PLC, Exact Therapeutics AS, Eracal Therapeutics and Sophia Genetics
SA. He has also been Chair of The American Pharmaceutical Group in
the UK, as well as a board member of the Association of British
Pharmaceutical Industry. Jean-Michel holds an MBA from the
Rotterdam School of Management (Erasmus University), The
Netherlands, as well as a PharmD and a PhD in Nuclear Chemistry and
Neurobiology from University Paris, France.
Dr John Chiplin, former Chairman of the Board of Scancell,
commented:
"The last 7 years have been transformative for Scancell, I am
leaving the Company with strong management and exciting prospects
ahead. I would like to welcome Dr Jean-Michel Cosséry to Scancell,
his extensive experience and accomplishments speak volumes and his
expertise in oncology and corporate management will be invaluable
as Scancell drive its immunotherapy products through the clinic,
with the aim to provide new treatment options for patients with
debilitating cancers."
Dr Jean-Michel Cosséry Chairman of the Board of Scancell,
said:
"I am delighted to be joining the Scancell team at this pivotal
time in the Company's evolution and to build on the rich history it
has in developing four innovate platforms. I am excited about the
clinical trials in progress and the life changing improvement these
important novel cancer therapies can bring to patients, while
enhancing shareholder value. I look forward to working with the
Board and the Senior Management Team as we seek to advance
Scancell's strategy."
Prof Lindy Durrant, Chief Executive Officer, Scancell,
added:
"I speak on the behalf of all of Scancell that we are excited to
welcome Jean-Michel and to capitalise on his experience as we
continue on our journey to deliver the next stage of growth. I am
deeply indebted to John Chiplin for his hard work, support and
boundless enthusiasm over the last 7 years which has allowed us to
build the Company into the strong business it is today."
Rule 17 and Schedule Two paragraph (g) of the AIM Rules for
Companies
The following information is disclosed pursuant to Rule 17 and
Schedule Two paragraph (g) of the AIM Rules for Companies in
relation to Jean-Michel Yves Sylvain Cosséry, aged 63:
Current Directorships Previous Directorships (last
5 years)
Malin Corporation Plc Diurnal Group Limited
Malin Life Sciences Holdings Ltd Kymab Group Limited
EXACT Therapeutics AS Lilly USA LLC
EraCal Therapeutics AG Immunocore Limited
SOPHiA GENETICS SA
SCI Elyna
--------------------------------- -----------------------------
Dr Cossery does not have an interest in any ordinary shares of
Scancell.
The Company confirms that there is no further information to be
disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the
AIM Rules for Companies.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014 (MAR).
For further information, please contact:
Scancell Holdings plc +44 (0) 20 3727 1000
Dr Jean-Michel Cosséry, Non-Executive
Chairman +44 (0) 20 7886 2500
Professor Lindy Durrant, CEO
Stifel Nicolaus Europe Limited (Nominated
Adviser and Joint Broker) +44 (0) 20 7710 7600
Nicholas Moore/ Samira Essebiyea/William Palmer-Brown
(Healthcare Investment Banking)
Nick Adams/Nick Harland (Corporate Broking)
Panmure Gordon (UK) Limited (Joint Broker) +44 (0) 20 7886 2500
Freddy Crossley/Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)
FTI Consulting +44 (0) 20 3727 1000
Simon Conway/Rob Winder/Alex Davis
About Scancell
Scancell is a clinical stage biopharmaceutical company that is
leveraging its proprietary research, built up over many years of
studying the human adaptive immune system, to generate novel
medicines to treat significant unmet needs in cancer and infectious
disease. The Company is building a pipeline of innovative products
by utilising its four technology platforms: Moditope(R) and
ImmunoBody(R) for vaccines and GlyMab(R) and AvidiMab(R) for
antibodies.
Adaptive immune responses include antibodies and T cells (CD4
and CD8), both of which can recognise damaged or infected cells. In
order to destroy such cancerous or infected cells, Scancell uses
either vaccines to induce immune responses or monoclonal antibodies
(mAbs) to redirect immune cells or drugs. The Company's unique
approach is that its innovative products target modifications of
proteins and lipids. For the vaccines (Moditope(R) and
ImmunoBody(R) ) this includes citrullination and homocitrullination
of proteins, whereas its mAb portfolio targets glycans or sugars
that are added onto proteins and / or lipids (GlyMab(R) ) or
enhances the potency of antibodies and their ability to directly
kill tumour cells (AvidiMab(R) ).
For further information about Scancell, please visit:
https://www.scancell.co.uk/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAKZGFMNMFGFZM
(END) Dow Jones Newswires
February 01, 2023 02:00 ET (07:00 GMT)
Scancell (LSE:SCLP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Scancell (LSE:SCLP)
Historical Stock Chart
From Apr 2023 to Apr 2024